Description
SWOT ANALYSIS OF CADILA HEALTHCARE
Cadila Healthcare
Parent Company
Cadila Healthcare
Category
Pharmaceuticals
Sector
Healthcare Industry
Tagline/ Slogan
The care continues
An integrated healthcare solutions provider, catering to over 45 USP therapeutic segments.
STP
Respiratory agents, cardiovascular, haematinics, gastrointestinal, analgesics, anti-infective and antibiotics, anti- diabetics and Segment immunological.
Diagnostic, preventive and curative pharmaceutical and diagnostic Target Group product seeking healthcare professionals
Marketing of the pharma products to assuage, identify and thwart Positioning diseases.
SWOT Analysis
1.USFDA approved plant for clinical trials 2.Sole manufacturer in Indian of Streptokinase and Hyaluronic Acidbased products 3. Caters to over 45 therapeutic areas and has presence in over 90 countries 4. Cadila has acquired Bio-chem which is major player in anti-infective segment in domestic market Strength 5. Recommercialisation of Urokinase through partnership with Microbix
1. Tough competition means the market share is limted Weakness 2. Weak international presence compared to a few international brands
1. Large penetration strategies in the therapeutic market to increase the market share Opportunity 2. increasing prevalence of chronic diseases such as diabetes, cancer
3. Penetration of medical insurance
1. Debt in the foreign currency and weak rupee may cause MTM 2. Economic fluctuations and emergence of global players Threats 3. Govt policies and restrictions in the medical field
Competition
1. Sun Pharma 2. Dr Reddys Labs 3. Cipla 4. Lupin Competitors 5. Ranbaxy
doc_121807513.docx
SWOT ANALYSIS OF CADILA HEALTHCARE
Cadila Healthcare
Parent Company
Cadila Healthcare
Category
Pharmaceuticals
Sector
Healthcare Industry
Tagline/ Slogan
The care continues
An integrated healthcare solutions provider, catering to over 45 USP therapeutic segments.
STP
Respiratory agents, cardiovascular, haematinics, gastrointestinal, analgesics, anti-infective and antibiotics, anti- diabetics and Segment immunological.
Diagnostic, preventive and curative pharmaceutical and diagnostic Target Group product seeking healthcare professionals
Marketing of the pharma products to assuage, identify and thwart Positioning diseases.
SWOT Analysis
1.USFDA approved plant for clinical trials 2.Sole manufacturer in Indian of Streptokinase and Hyaluronic Acidbased products 3. Caters to over 45 therapeutic areas and has presence in over 90 countries 4. Cadila has acquired Bio-chem which is major player in anti-infective segment in domestic market Strength 5. Recommercialisation of Urokinase through partnership with Microbix
1. Tough competition means the market share is limted Weakness 2. Weak international presence compared to a few international brands
1. Large penetration strategies in the therapeutic market to increase the market share Opportunity 2. increasing prevalence of chronic diseases such as diabetes, cancer
3. Penetration of medical insurance
1. Debt in the foreign currency and weak rupee may cause MTM 2. Economic fluctuations and emergence of global players Threats 3. Govt policies and restrictions in the medical field
Competition
1. Sun Pharma 2. Dr Reddys Labs 3. Cipla 4. Lupin Competitors 5. Ranbaxy
doc_121807513.docx